Abstract
Trafficking of macromolecular immunotherapy agent into the tumor microenvironment (TME) is a challenging issue. In the TME, cancer cells exploit indoleamine 2, 3-dioxygenase (IDO), as a cytosolic enzyme that catalyzes the L-tryptophan (Trp) through the kynurenine (Kyn) pathway, which could negatively regulate the activity of T cells. Thus, Trp/Kyn pathway, can be targeted with novel treatment modalities such as IDO1 inhibitor to benefit patients with aggressive solid tumors.
| Original language | English |
|---|---|
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| Journal | BioImpacts |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2019 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019 The Author(s).
ASJC Scopus Subject Areas
- General Biochemistry,Genetics and Molecular Biology
- Pharmaceutical Science
Keywords
- 3-dioxygenase
- Cancer therapy
- IDO inhibitor
- Immunotherapy
- Indoleamine 2
- Kynurenine
- Solid tumors
Fingerprint
Dive into the research topics of 'Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: Challenges and opportunities'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS